retatrutide 30mg reconstitution (RETA) – Research Peptide Retatrutide Analog GLP-3RT Research Peptide

Preliminary data suggest that GLP-1 RA use does not increase the risk of cancer recurrence and may reduce cardiovascular morbidity

This product is for research use only not for human or animal consumption

10.3389/fnmol.2016.00162 203 WangY.QuR.HuS.XiaoY.JiangX.XuG

These changes can support fat loss goals but warrant attention to ensure adequate nutrition

Jul 2011;141(7):1355-61

Safety and Candidacy Who May Be a Good Candidate Athletes training at high intensity or volume with significant electrolyte losses Endurance athletes competing in multi-day events Athletes with post-exercise GI distress that limits oral rehydration Those with documented electrolyte deficiencies contributing to cramping or fatigue Athletes who want medically supervised recovery support alongside nutrition and physical therapy Who Should Avoid IV Therapy Severe kidney disease (impaired fluid and electrolyte handling) Congestive heart failure (fluid overload risk) Known allergies to any components of the infusion Active infection or fever Uncontrolled hypertension Always disclose your complete medical history and medication list to your clinician before your first session